Inder Kaul

Bristol-Myers Squibb (Germany) — Germany

Medicine · Health Sciences

11h-index1.2kcitations46works10.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Schizophrenia research and treatment(18), Bipolar Disorder and Treatment(8), Blood Coagulation and Thrombosis Mechanisms(8), Sepsis Diagnosis and Treatment(6), Tryptophan and brain disorders(6)

Publications46 total

A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 2: Perceived Changes in Subjective Quality of Life and Medication Satisfaction
Schizophrenia Bulletin Open·2026Open Access
A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride For Schizophrenia, Part 1: Perceived Impact on Symptoms
Schizophrenia Bulletin Open·2026Open Access
Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension Trial
American Journal of Psychiatry·2026· 2 cited
Long-term efficacy, safety, and tolerability of xanomeline and trospium chloride in schizophrenia: A 52-week, open-label trial (EMERGENT-5)
Schizophrenia Research·2026
Measurement of schizophrenia symptoms through speech analysis from PANSS interview recordings
Frontiers in Psychiatry·2025· 2 citedOpen Access
Xanomeline and Trospium Chloride for the Treatment of Agitation Associated With Schizophrenia
The Journal of Clinical Psychiatry·2025· 4 citedOpen Access
Author Correction: Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials
Schizophrenia·2025· 1 citedOpen Access
From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials
The International Journal of Neuropsychopharmacology·2025· 8 citedOpen Access
Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia
The Journal of Clinical Psychiatry·2025· 8 citedOpen Access
EFFICACY OF KARXT ON NEGATIVE SYMPTOMS IN ACUTE SCHIZOPHRENIA: AN ANALYSIS OF POOLED DATA FROM 3 TRIALS
The International Journal of Neuropsychopharmacology·2025· 1 citedOpen Access
SAFETY AND EFFICACY OF KARXT IN PATIENTS WITH SCHIZOPHRENIA IN THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EMERGENT TRIALS
The International Journal of Neuropsychopharmacology·2025· 4 citedOpen Access
Capturing changes in social functioning and positive affect using ecological momentary assessment during a 12-month trial of xanomeline and trospium chloride in schizophrenia
Schizophrenia Research·2025· 4 citedOpen Access
Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials
Schizophrenia·2024· 23 citedOpen Access
Safety and Tolerability of KarXT (Xanomeline Trospium): Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials
CNS Spectrums·2024· 1 citedOpen Access
Pooled Analysis of EPS-Like Symptoms in the EMERGENT Program of KarXT in Schizophrenia
CNS Spectrums·2024· 1 citedOpen Access
Efficacy of KarXT (Xanomeline Trospium) in Schizophrenia: Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials
CNS Spectrums·2024· 1 citedOpen Access
Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials
Schizophrenia Research·2024· 38 citedOpen Access
Gaining trust through transparency: the EMERGENT-2 trial – Authors' reply
The Lancet·2024· 1 citedOpen Access
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia
JAMA Psychiatry·2024· 133 citedOpen Access
412. Efficacy of Karxt on Negative Symptoms in Acute Schizophrenia: A Post Hoc Analysis of Participants With Prominent Negative Symptoms
Biological Psychiatry·2024
page 1 of 3Next →

Frequent Co-authors

Stephen K. Brannan(21), Amy Claxton(15), Jawed Fareed(13), Sharon Sawchak(13), Debra Hoppensteadt(12), Colin Sauder(11), Andrew Miller(9), Josephine Cunanan(8), Yutaka Osawa(7), Kazuhisa Tsuruta(6), Steven M. Paul(6), Stephen Kanes(5), Haiyuan Zhu(5), David P. Walling(5), Andrew C. Miller(5), Joe Hirman(4), Abdul J. Sankoh(4), James Doherty(4), Alan Breier(4), Steven M. Paul(4)